Impact of New Cell and Gene Therapies on Utilization of BMT and HSCT

Over the last ten years, there has been tremendous global investment in novel cell and gene therapies, many of which are being studied for indications that have long been treated with BMT and HSCT. In this session, a panel of industry and clinical experts explore how growth in novel cell and gene therapy approvals could impact the future use of BMT and HSCT.

Speakers:

• Richard Jones, MD, Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
• Joseph McGuirk, DO, Professor of Medicine, University of Kansas Cancer Center
• Leonard Sender, MD, Senior Vice President, Medical Affairs for Pediatric, Adolescent and Young Adult Oncology, NantKwest
• Chris McClain, Vice President, Sales – Commercial Entities, Be The Match BioTherapies